Skip to content
⌘KStart free
AI InfrastructureDefenseQuantumAll studies →

Biotech catalyst calendar

registry pull 2026-08-19

Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

upcoming primary completions across every covered company, by month sources →

Upcoming readout windows

next 90 days · by month

371 studies across 145 companies, in the next 90 days.

August 2026 94

TickerNameFamousShortStudyPhaseStatusPrimary completionReadout inUpdated
AZNAstraZeneca201.0dStudy Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an IleostomyNCT06681324Number of participants with adverse eventsPhase 2Active, not recruiting2026-08-20today2026-06-01
AZNAstraZeneca201.0dProspective Observational Multicenter Study of Patients With AH and CKD Markers in Kazakhstan (PROGRESS-CKD)NCT06744335observationalThe proportion of patients with markers of chronic kidney disease (CKD) among patients with arterial hypertension such as: albuminuria/proteinuria; GFR <60 ml/min/1.73 m2 (CFR categories C3a-C5).—Active, not recruiting2026-08-20today2026-07-08
SNYSanofi172.7dRSV Immunisation Status in Queensland (Australia)NCT07615192observationalThe proportion of immunised infants among all enrolled infants—Recruiting2026-08-20today2026-07-31
NVONovo Nordisk A/S192.9dA Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyNCT06797869Change in weekly average Pain Intensity-Numerical Rating Scale (PI-NRS)Phase 2Active, not recruiting2026-08-21in 1 d2025-12-05
PFEPfizer194.2dA Study to Learn How Different Amounts of the Study Medicine Called PF-07999415 Are Tolerated and Act in the Body in Healthy AdultsNCT06965465Number of participants with treatment emergent adverse events.Phase 1Active, not recruiting2026-08-21in 1 d2026-07-23
REGNRegeneron Pharmaceuticals233.9dA Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement TherapyNCT05568459observationalAnnualized bleeding rate (ABR)—Active, not recruiting2026-08-21in 1 d2026-08-07
PFEPfizer194.2dA Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid TumorsNCT05262400Dose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cyclePhase 1/2Active, not recruiting2026-08-23in 3 d2024-11-18
AZNAstraZeneca201.0dA Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseaseNCT04711252Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST) version 1.1Phase 3Active, not recruiting2026-08-24in 4 d2025-10-14
BIIBBiogen194.7dA Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their PregnancyNCT07047820observationalChange From Baseline in Edinburgh Postnatal Depression Scale (EPDS) at Day 15—Recruiting2026-08-24in 4 d2025-08-03
REGNRegeneron Pharmaceuticals233.9dA Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With SurgeryNCT06161441Pathological complete response (pCR) as evaluated by blinded independent pathological review (BIPR) in post-treatment resected tumor samplesPhase 2Active, not recruiting2026-08-24in 4 d2026-08-10
CLRBCellectar Biosciences, Inc.13.9dDose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and SarcomasNCT03478462Number of participants with dose limiting toxicities (DLT)Phase 1Active, not recruiting2026-08-25in 5 d2026-03-18
SNYSanofi172.7dA Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' DiseaseNCT06984627Percent change from baseline in FT4 levelsPhase 2Recruiting2026-08-25in 5 d2026-07-07
AMGNAmgen185.2dEffect of Maridebart Cafraglutide on the Heart's Electrical ActivityNCT07229157Change from Baseline in QTcF for Maridebart CafraglutidePhase 1Active, not recruiting2026-08-26in 6 d2026-01-23
SNYSanofi172.7dTeplizumab in Pediatric Stage 2 Type 1 DiabetesNCT05757713Treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), TEAEs leading to withdrawal, and serious adverse events (SAEs)Phase 4Active, not recruiting2026-08-27in 7 d2026-01-30
AZNAstraZeneca201.0dA Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLCNCT04995523Percentage of participants with adverse events (AEs) and immune mediated AEs (imAEs), serious AEs (SAEs), dose limiting toxicities (DLTs), vital signs, and abnormal laboratory parametersPhase 1/2Active, not recruiting2026-08-28in 8 d2026-07-14
AZNAstraZeneca201.0dA Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy ParticipantsNCT07534592Area under concentration-time curve from time 0 to infinity (AUCinf) of atorvastatinPhase 1Active, not recruiting2026-08-28in 8 d2026-06-24
BSXBoston Scientific Corporation271.0dSpaceIT Hydrogel System for Perirectal SpacingNCT06451614Primary Safety Endpoint - Acute Grade 3 or greater adverse events.Not applicableActive, not recruiting2026-08-30in 10 d2026-08-12
GENBGenerate Biomedicines515.3dStudy to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult ParticipantsNCT06920693Composite Outcome: To assess the safety and tolerability of single doses of GB-7624 administered subcutaneously (SC) in healthy volunteers.Phase 1Active, not recruiting2026-08-30in 10 d2025-12-05
MSLESatellos Bioscience, Inc.31.7dAn Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101NCT06867107Treatment emergent adverse eventsPhase 2Enrolling by invitation2026-08-30in 10 d2026-04-23
PFEPfizer194.2dMagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)NCT06152575Progression free survival per International Myeloma Working Group criteriaPhase 3Recruiting2026-08-30in 10 d2026-08-14
PFEPfizer194.2dA Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLCNCT07556549observationalAge at Start of Lorlatinib Treatment—Active, not recruiting2026-08-30in 10 d2026-08-10
TELATela Bio Inc210.5dA Retrospective Assessment of OviTex PRS (OviTex)NCT05736848observationalThe occurrence of relevant (S)AEs within 24 months of OviTex® PRS implantation.—Active, not recruiting2026-08-30in 10 d2026-08-18
4151.TKyowa Kirin Co., Ltd.——Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular DegenerationNCT06116890Reduction of 15 or more letters in BCVA (Best corrected visual acuity) as measured by ETDRS visual acuity chart from baselinePhase 2Active, not recruiting2026-08-31in 11 d2025-10-30
4151.TKyowa Kirin Co., Ltd.——Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular EdemaNCT06116916Reduction of 15 or more letters in BCVA (Best corrected visual acuity) as measured by ETDRS visual acuity chart from baselinePhase 2Active, not recruiting2026-08-31in 11 d2025-10-30
4568.TDaiichi Sankyo0—Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)NCT04704934Overall Survival in Participants Who Were Administered Trastuzumab Deruxtecan Compared With Ramucirumab in Combination With PaclitaxelPhase 3Active, not recruiting2026-08-31in 11 d2026-05-27
ABBVAbbVie224.0dA Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid TumorsNCT02099058Number of Participants with Adverse EventsPhase 1Active, not recruitingAug 2026≤ 11 d2025-08-14
ABBVAbbVie224.0dA Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.NCT03539744Progression-Free Survival (PFS)Phase 3Active, not recruitingAug 2026≤ 11 d2025-06-19
ABBVAbbVie224.0dRGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)NCT04514653Mean change from baseline in BCVA to Week 40 based on the Early Treatment Diabetic Retinopathy Study (ETDRS) scorePhase 2Active, not recruitingAug 2026≤ 11 d2026-02-27
ABBVAbbVie224.0dA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to DupilumabNCT06389136Participants who achieve at least a 90% reduction in Eczema Area and Severity Index from Baseline (EASI 90)Phase 3RecruitingAug 2026≤ 11 d2026-07-06
ABBVAbbVie224.0dA Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult ParticipantsNCT07032597Percentage of Participants Achieving "Responder" Status Based on the Evaluating Investigator's (EI) Live Assessment of Mid-Face Volume Deficit Scale (MFVDS)Phase 3Active, not recruitingAug 2026≤ 11 d2025-08-14
ABBVAbbVie224.0dA Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye DiseaseNCT07284381Change from Baseline in Ocular Surface Disease Index (OSDI) ScorePhase 3Active, not recruitingAug 2026≤ 11 d2026-06-17
ACRSAclaris Therapeutics, Inc.108.7dATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic DermatitisNCT07011706Percent Change in Eczema Area and Severity Index (EASI)Phase 2Active, not recruitingAug 2026≤ 11 d2026-03-25
AKBAAkebia Therapeutics108.8dTo Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center HemodialysisNCT06901505Change in hemoglobin (Hb)Phase 3Active, not recruitingAug 2026≤ 11 d2026-02-23
ANROAlto Neuroscience87.5dALTO-100 in Bipolar Disorder With Depression (BD-D)NCT06656416To assess efficacy of ALTO-100 versus placebo on depression symptoms in bipolar disorder in a pre-defined subgroup of participants as measured by the mean change from Day 1 to Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total scorePhase 2RecruitingAug 2026≤ 11 d2025-07-16
AVIRAtea Pharmaceuticals, Inc.818.0dDrug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or MethadoneNCT07314346Effect of BEM/RZR on PK of buprenorphine,norbuprenorphine and naloxonePhase 1RecruitingAug 2026≤ 11 d2026-07-16
AZNAstraZeneca201.0dA Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in BrazilNCT06008353observationalDemographic Characteristics of the Cohort—Active, not recruiting2026-08-31in 11 d2024-12-19
AZNAstraZeneca201.0dBoosting Regional Integration for COP D Care Through Guided Implementation and Audit of Post Exacerbation Transition BundleNCT06646419observationalTime to CID.—Active, not recruiting2026-08-31in 11 d2026-08-13
BIVIBioVie Inc.34.4dNE3107 in Adults With Neurological Symptoms of Long COVIDNCT06847191Change from Baseline in performance on the Cogstate Cognition battery*Phase 2Active, not recruitingAug 2026≤ 11 d2026-05-29
BLCOBausch & Lomb Incorporated185.9dA Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Trial ParticipantsNCT07717918Ocular pain severity assessed by numeric pain rating scale (NPRS)Phase 1RecruitingAug 2026≤ 11 d2026-07-21
BMRNBioMarin Pharmaceutical227.4dRapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to PalynziqNCT06780332To determine if RDD to Palynziq improves drug tolerability and treatment persistence in adults with PKU experiencing HSRs leading to treatment interruption or reduction of dose or dosing frequency (reactive HSR).Phase 4Active, not recruitingAug 2026≤ 11 d2026-04-03
BMYBristol-Myers Squibb224.6dA Phase 1 Study of Navlimetostat Tablet FormulationsNCT07544628Maximum Plasma Concentration (Cmax)Phase 1Recruiting2026-08-31in 11 d2026-06-24
BSXBoston Scientific Corporation271.0dRespiration Measured Via End-tidal CO2 and Spirometry Study (RESPI)NCT07537478observationalRespiratory rate detection - end tidal CO2—RecruitingAug 2026≤ 11 d2026-08-12
CADLCandel Therapeutics, Inc.1310.4dA Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene BesadenovecNCT07332000Biodistribution of aglatimagene besadenovecPhase 2RecruitingAug 2026≤ 11 d2026-03-20
CINPHA.STCinclus Pharma Holding AB——A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)NCT07037875Healing of EE at Week 4 as assessed by endoscopy in participants with Baseline EE LA grades C/D.Phase 3Active, not recruitingAug 2026≤ 11 d2026-08-04
CORTCorcept Therapeutics136.4dRelacorilant in Combination With Different Treatment Regimens in Patients With Gynecological CancersNCT06906341Progression-Free Survival (PFS)Phase 2RecruitingAug 2026≤ 11 d2026-07-16
CORTCorcept Therapeutics136.4dEvaluation of Miricorilant on Liver Fat in Patients With MASLDNCT06947304Change in fasting hepatic lipogenesis after 6 weeks of treatmentPhase 1Active, not recruitingAug 2026≤ 11 d2026-07-30
CRISCuris, Inc.21.8dCA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)NCT03328078Part A: To determine the safety and tolerability of emavusertib as a monotherapy and in combination with ibrutinib: dose-limiting toxicity (DLT)Phase 1/2RecruitingAug 2026≤ 11 d2026-04-16
CYTKCytokinetics209.6dA Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)NCT06081894Change in Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS)Phase 3Active, not recruitingAug 2026≤ 11 d2026-08-05
ENSCEnsysce Biosciences31.0dPF614 Analgesic Activity in Acute Postoperative Pain (PF614-301)NCT06602271Pain NRS-R area under the curve through 48 hours (AUC4-48)Phase 3RecruitingAug 2026≤ 11 d2026-01-22
EXELExelixis1613.4dA Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid TumorsNCT03845166Dose-Escalation Stage: MTD/recommended dose for XL092Phase 1Active, not recruiting2026-08-31in 11 d2024-11-19
GEHCGE Healthcare212.9dData Collection of New Spectral CT Imaging MethodNCT07661706observationalEvaluable Raw Research Scans—RecruitingAug 2026≤ 11 d2026-06-22
GILDGilead Sciences233.9dStudy of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01NCT06727565Objective response rate (ORR)Phase 2Active, not recruitingAug 2026≤ 11 d2026-03-02
GKOSGlaukos Corporation203.6dSafety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery AloneNCT06848946Change from baseline in mean diurnal IOPPhase 4RecruitingAug 2026≤ 11 d2026-01-21
GPCRGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics1011.4dAleniglipron Phase 2 Body Composition StudyNCT07169942Percent change in total body fat mass by DXAPhase 2Active, not recruitingAug 2026≤ 11 d2026-03-03
HLNHALEON191.3dClinical Study to Investigate the Antihypersensitivity Efficacy of a Novel DentifriceNCT07215767Change from Baseline in Schiff sensitivity score at Week 8 (Test Dentifrice Versus [Vs] Reference Dentifrices 1, 2 and 3)Phase 3Active, not recruitingAug 2026≤ 11 d2026-06-16
HROWHarrow Inc811.8dStudy Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal InjectionsNCT07456826Proportion of Participants Achieving Successful Ocular Surface AnesthesiaPhase 4Enrolling by invitationAug 2026≤ 11 d2026-04-07
IGCIGC Pharma, LLC41.7dClinical Trial on Agitation in Alzheimer's DementiaNCT05543681AgitationPhase 2RecruitingAug 2026≤ 11 d2026-05-20
INBSIntelligent Bio Solutions Inc.01.0dInterference and Stability Evaluation of the Intelligent Fingerprinting Drug Screening SystemNCT07758907Effect of Potential InterferentsNot applicableEnrolling by invitationAug 2026≤ 11 d2026-08-11
IPN.PAIpsen0—A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial LinesNCT04821089Incidence of treatment emergent adverse events (TEAEs) at each dosePhase 1/2Active, not recruiting2026-08-31in 11 d2026-07-28
ISRGIntuitive Surgical251.4dA Study to Understand the Utility of the Force Feedback Instruments in Robotic Procedures Using da Vinci 5 RobotNCT06879912observationalTo assess the force imparted on the tissue by force feedback instruments.—RecruitingAug 2026≤ 11 d2026-02-25
IVVDInvivyd, Inc.98.9dStudy of VYD2311 for the Prevention of COVID-19NCT07298434RT-PCR-confirmed symptomatic COVID-19 through Day 90Phase 3Active, not recruitingAug 2026≤ 11 d2026-06-10
IVVDInvivyd, Inc.98.9dSafety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 VaccineNCT07655180Assessment of safety based on treatment emergent adverse events, injection site reactions, and hypersensitivity reactions through day 6Phase 3RecruitingAug 2026≤ 11 d2026-06-17
KMBKimberly-Clark Corporation1614.7dTampon Safety-in-Use StudyNCT07561905Incidence of Tampon Related Adverse EventsNot applicableRecruiting2026-08-31in 11 d2026-08-10
KODKodiak Sciences Inc1220.6dA Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAKNCT06556368Best corrected visual acuity (BCVA)Phase 3Active, not recruitingAug 2026≤ 11 d2026-04-29
KPTIKaryopharm Therapeutics Inc72.7dSelinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaNCT05611931Investigator assessed Progression Free Survival (PFS) per RECIST v1.1Phase 3Active, not recruitingAug 2026≤ 11 d2026-05-29
KURAKura Oncology, Inc.1111.8dSafety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaNCT06001788Rate of dose limiting toxicities (DLTs) per dose levelPhase 1RecruitingAug 2026≤ 11 d2026-04-14
KYTXKyverna Therapeutics128.7dKYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus NephritisNCT05938725Incidence adverse events (AEs) and laboratory abnormalities (Phase 1 and Phase 2)Phase 1/2Active, not recruitingAug 2026≤ 11 d2025-10-29
LLYEli Lilly and Company293.9dA Study of LY3971297 in Healthy ParticipantsNCT06148272Part A and F: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationPhase 1Active, not recruitingAug 2026≤ 11 d2026-07-16
LLYEli Lilly and Company293.9dEffect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)NCT06260722Change from Baseline in Hemoglobin A1c (HbA1c) (%)Phase 3Active, not recruitingAug 2026≤ 11 d2026-04-13
LLYEli Lilly and Company293.9dComparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach AcidNCT06916143Pharmacokinetic (PK): Area Under the Concentration Curve from 0 to Infinity (AUC0-∞) of LY4100511 (DC-853)Phase 1Active, not recruitingAug 2026≤ 11 d2026-07-16
LLYEli Lilly and Company293.9dA Study of LY3867070 in Healthy ParticipantsNCT07021547Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) Considered by the Investigator to be Related to Study Drug AdministrationPhase 1RecruitingAug 2026≤ 11 d2026-06-03
LLYEli Lilly and Company293.9dA Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver ImpairmentNCT07165002Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3537031Phase 1RecruitingAug 2026≤ 11 d2025-12-04
LLYEli Lilly and Company293.9dA Study of Retinal Imaging to Detect Abnormal Protein Deposits Associated With Alzheimer's DiseaseNCT07254234observationalPercentage of Participants with the Same Results on the Blood Test and Retinal Scan—Not yet recruitingAug 2026≤ 11 d2025-11-28
LLYEli Lilly and Company293.9dA Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes MellitusNCT07313813Percentage of Fasting Participants with Lack of Gastric Content Retention Post-Solid Test MealPhase 1Active, not recruitingAug 2026≤ 11 d2026-04-16
LLYEli Lilly and Company293.9dA Study of Remternetug (LY3372993) in Healthy Chinese ParticipantsNCT07346495Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationPhase 1Active, not recruitingAug 2026≤ 11 d2026-06-17
LLYEli Lilly and Company293.9dA Study of Eltrekibart (LY3041658) in Healthy ParticipantsNCT07545590Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3041658Phase 1RecruitingAug 2026≤ 11 d2026-06-23
MANEVeradermics, Inc.106.9dSafety and Efficacy of VDPHL01 in Males and Females With AGANCT06527365Changes in non-vellus Total Area Hair Count (TAHC)Phase 2Active, not recruitingAug 2026≤ 11 d2025-11-06
MDXGMiMedx Group, Inc.125.3dModified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUsNCT06600724Percentage of target ulcers achieving wound closureNot applicableRecruitingAug 2026≤ 11 d2024-09-19
MIRMMirum Pharmaceuticals, Inc.1012.1dA Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)NCT07298330Percentage of participants with a composite endpoint of virologic response and ALT normalization at Week 24 in brelovitug arms compared to response at Week 12 of delayed-treatment armPhase 3Active, not recruitingAug 2026≤ 11 d2026-06-29
MMSIMerit Medical Systems, Inc.163.7dPREEMIE: Study for Treatment of PDA in Premature InfantsNCT06587282Safety EndpointNot applicableActive, not recruitingAug 2026≤ 11 d2026-05-15
NRIXNurix Therapeutics, Inc.1018.0dA Study of NX-1607 in Adults With Advanced MalignanciesNCT05107674Incidence of treatment-emergent adverse events (TEAEs), including Grade ≥ 3 TEAEs, treatment-emergent serious adverse events (SAEs), TEAEs leading to study drug discontinuation, and deaths due to TEAEsPhase 1Recruiting2026-08-31in 11 d2025-09-09
NTRANatera, Inc.184.7dLAMBDA 002 (Lung Registry) StudyNCT05170425observationalPercent of donor-derived cell-free DNA (ddcfDNA) measured via the Prospera test—Active, not recruitingAug 2026≤ 11 d2025-05-22
NVONovo Nordisk A/S192.9dA Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in ChinaNCT07456774observationalTime to 3P major adverse cardiovascular events—Enrolling by invitation2026-08-31in 11 d2026-05-20
PFEPfizer194.2dA Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.NCT07543380Percentage of participants reporting prompted local reactions within 7 days following investigational product administrationPhase 3Recruiting2026-08-31in 11 d2026-06-02
PFEPfizer194.2dA Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy AdultsNCT07594769Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUCinf) of the test and reference formulationsPhase 1Recruiting2026-08-31in 11 d2026-06-10
RADXRadiopharm Theranostics, Ltd01.0dSafety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid TumorsNCT05799274Radiation dosimetry of RAD301Phase 1RecruitingAug 2026≤ 11 d2026-07-17
RCUSArcus Biosciences, Inc.1411.6dA Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the BodyNCT05568095Overall survivalPhase 3Active, not recruitingAug 2026≤ 11 d2026-07-31
RIGLRigel Pharmaceuticals910.6dStudy of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)NCT05308264Safety and TolerabilityPhase 1/2RecruitingAug 2026≤ 11 d2026-08-10
SGHTSight Sciences, Inc.115.5dOMNI 3.1 Surgical System in Subjects With Primary Open-Angle GlaucomaNCT06991270Primary Effectiveness EndpointNot applicableRecruiting2026-08-31in 11 d2026-01-14
SNYSanofi172.7dValidation of Chlamydia Diagnostic Codes in TriNetX US EHR DataNCT07094373observationalValidity of ICD-10-CM Diagnostic Codes for Chlamydial Infections—Recruiting2026-08-31in 11 d2026-07-10
TMDXTransMedics129.5dOCS Heart EXPAND + CAP Continued Follow-UpNCT05096299observationalPatient survival—Active, not recruitingAug 2026≤ 11 d2025-04-09
VSTMVerastem, Inc.99.3dStudy of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic CancerNCT05669482Part A: To determine RP2D for avutometinib (VS-6766) and defactinib in combination gemcitabine and nab-paclitaxelPhase 1/2Active, not recruiting2026-08-31in 11 d2025-09-02
XENEXenon Pharmaceuticals Inc.167.3dA Randomized Study of Azetukalner Versus Placebo in Major Depressive DisorderNCT06775379Change from baseline in the Hamilton Depression Rating Scale, 17-item (HAMD-17) score at Week 6Phase 3RecruitingAug 2026≤ 11 d2026-08-03
ZBHZimmer Biomet194.9dPMCF Study on the Safety, Performance and Clinical Benefits Data of the ComposiTCPNCT07080450observationalAssessment of performance by analyzing soft tissue to bone healing in the shoulder (rotator cuff)—RecruitingAug 2026≤ 11 d2026-02-03

September 2026 126

TickerNameFamousShortStudyPhaseStatusPrimary completionReadout inUpdated
ARDXArdelyx1111.0dStudy to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 YearsNCT056435346/12-week APS (abdominal pain and SBM) +2 responsePhase 3Active, not recruiting2026-09-01in 12 d2026-06-04
INCYIncyte Corporation184.8dTafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL PatientsNCT04824092PFS-INVPhase 3Active, not recruiting2026-09-01in 12 d2026-04-01
NVONovo Nordisk A/S192.9dA Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney DiseaseNCT06717698Change in urinary albumin-to-creatinine ratio (UACR) at week 12Phase 2Recruiting2026-09-01in 12 d2026-03-11
PFEPfizer194.2dTACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)NCT05548127Phase 1b: number of participants with dose limiting toxicitiesPhase 1/2Active, not recruiting2026-09-01in 12 d2026-02-10
PFEPfizer194.2dA Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial HypertensionNCT06137742Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Phase 1/2Active, not recruiting2026-09-02in 13 d2026-05-19
AMGNAmgen185.2dComparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.NCT07545226Area Under the Concentration-time Curve (AUC) from Time 0 Extrapolated to Infinity (AUCinf) of EvolocumabPhase 1Active, not recruiting2026-09-03in 14 d2026-07-20
AZNAstraZeneca201.0dA Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain CancerNCT03423628Incidence of dose-limiting toxicities (DLTs)Phase 1Active, not recruiting2026-09-03in 14 d2026-07-17
INCYIncyte Corporation184.8dA Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult ParticipantsNCT07588139Pharmacokinetics Parameter (PK): Cmax of dermal interstitial fluid (dISF) ruxolitinibPhase 1Recruiting2026-09-03in 14 d2026-06-03
NVONovo Nordisk A/S192.9dA Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body WeightNCT07605052AUCss: area under the total cagrilintide concentration-time curve at steady state after 5th dosing of cagrilintidePhase 1Active, not recruiting2026-09-03in 14 d2026-08-17
PFEPfizer194.2dA Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy AdultsNCT07597928Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)Phase 1Recruiting2026-09-03in 14 d2026-06-15
SNYSanofi172.7dEfficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus ErythematosusNCT05039840Percentage of participants who achieved a Systemic Lupus Erythematosus Responder Index (SRI-4) response at Week 24.Phase 2Active, not recruiting2026-09-03in 14 d2026-08-06
BMYBristol-Myers Squibb224.6dA Study of BMS-986490 With or Without Bevacizumab in Advanced Solid TumorsNCT06730750Number of participnats with Adverse Events (AEs)Phase 1/2Recruiting2026-09-05in 16 d2026-07-02
HLUN-B.COH. Lundbeck A/S0—A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic MigraineNCT04965675Change From Baseline in Monthly Migraine Days (MMDs) Averaged Over Weeks 1-12Phase 3Recruiting2026-09-05in 16 d2026-07-14
IBAB.BRIon Beam Applications——Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei)NCT07137195Short term efficacy evaluationNot applicableActive, not recruiting2026-09-05in 16 d2026-02-27
MDAIAI-Spectral214.5dReal-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker DetectionNCT07446582observationalAssessment of equivalency in sensitivity and specificity of the DeepMSI AI system compared with experienced clinicians for detection of AMD biomarkers.—Recruiting2026-09-05in 16 d2026-03-11
ALK-B.COALK-Abelló A/S——A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65NCT07060885Average daily total combined rhinitis score (TCRS) during the primary efficacy assessment period.Phase 3Active, not recruiting2026-09-06in 17 d2026-07-20
AZNAstraZeneca201.0dA Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy AdultsNCT07622433Area under concentration-time curve from time 0 to infinity (AUCinf)Phase 1Active, not recruiting2026-09-07in 18 d2026-07-28
PFEPfizer194.2dA Study to Learn About How Food Affects the Uptake of Study Medicine Prifetrastat Into the Blood in Healthy AdultsNCT07731100Area under the concentration-time curve from time zero to extrapolated infinite time (AUCinf) for PrifetrastatPhase 1Not yet recruiting2026-09-10in 21 d2026-07-28
SNYSanofi172.7dAgalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in TaiwanNCT06052800observationalCohort 1: change of Left ventricular mass index (LVMI) as measured by echocardiography in agalsidase beta-treated patients—Active, not recruiting2026-09-10in 21 d2026-05-15
NVONovo Nordisk A/S192.9dA Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 DiabetesNCT07087795Part A: Change in time in range (TIR) 3.9-10.0 mmol/L (70-80 mg/dL)Phase 1Active, not recruiting2026-09-12in 23 d2026-08-13
PFEPfizer194.2dA Study to Learn How the Study Medicine Called Etrasimod is Taken up Into Blood and Breastmilk of Healthy Breastfeeding WomenNCT07153159Area under the etrasimod concentration-time curve in breast milkPhase 1Recruiting2026-09-12in 23 d2026-04-07
000100.KSYuhan Corporation0—Bioequivalence Study Between YHP2508C and YHR2603 in Healthy SubjectsNCT07584304Area under the plasma drug concentration-time curve [AUCt]Phase 1Not yet recruiting2026-09-15in 26 d2026-05-13
HLUN-B.COH. Lundbeck A/S0—A Trial of Lu AG13909 in Adult Participants With Cushing's DiseaseNCT06471829Part A & Part B: Urinary Free Cortisol (UFC) Complete Response: mean UFC (mUFC) ≤ Upper Limit of Normal (ULN) at the end of the IV/SC Titration PeriodPhase 2Recruiting2026-09-15in 26 d2026-06-12
PFEPfizer194.2dA Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without DiabetesNCT06924320Occurrence of treatment-emergent adverse events (TEAEs)Phase 1/2Recruiting2026-09-15in 26 d2026-06-01
AZNAstraZeneca201.0dA Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234NCT07220954Maximum observed plasma concentration (Cmax)Phase 1Active, not recruiting2026-09-17in 28 d2026-08-13
VRTXVertex Pharmaceuticals Incorporated223.0dAn Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney TransplantNCT06832410Proportion of Participants who are Insulin IndependentPhase 3Recruiting2026-09-17in 28 d2026-03-23
SNYSanofi172.7diGlarLixi CGM Study in Chinese T2D Individuals After OADsNCT06671587Superiority of mean change in the percentage of TIR [3.9-10.0 mmol/L (70-180 mg/dL)]Phase 4Recruiting2026-09-18in 29 d2026-03-17
CRDLCardiol Therapeutics Inc.52.3dCardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)NCT06708299Recurrence of pericarditisPhase 3Recruiting2026-09-21in 32 d2026-08-13
PFEPfizer194.2dA Study to Learn About Somatrogon in Patients With Pediatric Growth Hormone Deficiency (p GHD) in India.NCT06587035observationalNumber of adverse events in participants on Somatrogon—Recruiting2026-09-21in 32 d2026-08-14
MRNAModernaTX, Inc.1710.2dStudy to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of AgeNCT05992935Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)Phase 1/2Active, not recruiting2026-09-22in 33 d2026-04-03
ONCBeOne Medicines142.4dA Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström MacroglobulinemiaNCT05952037Cohort 1: Major Response Rate (MRR)Phase 2Active, not recruiting2026-09-22in 33 d2026-01-02
PFEPfizer194.2dKorean Post-marketing Surveillance for Xeljanz XRNCT04876781observationalNumber of Participants With Treatment Emergent Adverse Events (AEs)—Recruiting2026-09-22in 33 d2026-08-03
SNYSanofi172.7dReal-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational StudyNCT05991323observationalFrequency of reasons for dupilumab treatment initiation with the description of dosing, frequency and duration of treatment—Active, not recruiting2026-09-22in 33 d2025-09-16
AZNAstraZeneca201.0dA Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.NCT06995820Number of participants with adverse events (AEs) and serious AEs.Phase 1Recruiting2026-09-23in 34 d2026-05-15
PFEPfizer194.2dStudy to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsNCT04557449Number of participants with dose limiting toxicities in the Dose Escalation PortionPhase 2Active, not recruiting2026-09-23in 34 d2025-10-01
PFEPfizer194.2dKorean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth HormoneNCT05509894observationalIncidence of adverse events (AEs)—Active, not recruiting2026-09-23in 34 d2026-01-27
VIRVir Biotechnology, Inc.1412.2dEffect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434NCT05484206Maximum observed Plasma concentration (Cmax) of VIR-2218 and metabolite AS(N-1)3'VIR2218Phase 1Recruiting2026-09-25in 36 d2025-06-13
BIIBBiogen194.7dA Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErythematosusNCT04961567Percentage of Participants Who Achieved a Systemic Lupus Erythematosus Responder Index of 4 (SRI-4) Response at Week 52Phase 3Active, not recruiting2026-09-27in 38 d2026-01-29
ONCBeOne Medicines142.4dA Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy AdultsNCT07628881Area under the Plasma Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-inf) for SonrotoclaxPhase 1Recruiting2026-09-27in 38 d2026-07-09
AZNAstraZeneca201.0dA Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2NCT07143604Objective Response Rate (ORR)Phase 2Active, not recruiting2026-09-28in 39 d2026-06-17
INCYIncyte Corporation184.8dA Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell CarcinomaNCT05888844Objective response rate (ORR)Phase 2Active, not recruiting2026-09-28in 39 d2026-08-17
MLTXMoonLake Immunotherapeutics AG186.6dAn Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)NCT06768671Pharmacokinetics (PK) of sonelokimab in adolescentsPhase 3Active, not recruiting2026-09-28in 39 d2026-05-06
OCGNOcugen921.6dA Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt DiseaseNCT05956626Change from baseline in atrophic lesion size as measured by Fundus Auto FluorescencePhase 2/3Active, not recruiting2026-09-28in 39 d2026-07-31
SNYSanofi172.7dStudy to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male ParticipantsNCT07726914AUClastPhase 1Not yet recruiting2026-09-28in 39 d2026-07-24
SNYSanofi172.7dLong-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical StudyNCT06033833Percentage of participants with treatment-emergent adverse eventsPhase 2Active, not recruiting2026-09-29in 40 d2026-05-20
4568.TDaiichi Sankyo0—A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)NCT06362252Number of Participants Reporting Dose-limiting Toxicities Following I-DXd in Combination With Atezolizumab With or Without Carboplatin (Part A)Phase 1/2Recruiting2026-09-30in 41 d2026-02-06
ABBVAbbVie224.0dA Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid TumorsNCT02988960Maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181Phase 1Active, not recruitingSep 2026≤ 41 d2026-01-09
ABBVAbbVie224.0dA Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or AdalimumabNCT06100744Percentage of Participants who Achieve >= 30% Improvement in Juvenile Idiopathic Arthritis American College of Rheumatology Response Criteria (JIA-ACR 30)Phase 3RecruitingSep 2026≤ 41 d2026-07-31
ABBVAbbVie224.0dA Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male ParticipantsNCT06953934Maximum Plasma Concentration (Cmax) of ABBV-932Phase 1Active, not recruitingSep 2026≤ 41 d2026-06-29
ABBVAbbVie224.0dA Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World SettingNCT07421258observationalPercentage of Participants Managed Using Treat-to-Target (T2T)—RecruitingSep 2026≤ 41 d2026-03-27
ABBVAbbVie224.0dA Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injection Moves Through the Body of Healthy Adult ParticipantsNCT07604558Number of Participants Experiencing Adverse EventsPhase 1RecruitingSep 2026≤ 41 d2026-06-24
ABBVAbbVie224.0dA Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresertib in Healthy Adult ParticipantsNCT07649954Maximum Observed Plasma Concentration (Cmax) of NacresertibPhase 1RecruitingSep 2026≤ 41 d2026-07-23
ABVXAbivax S.A.135.0dStudy to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet FormulationNCT07453784Maximum Plasma Concentration (Cmax)Phase 1RecruitingSep 2026≤ 41 d2026-04-06
ALKSAlkermes, Inc.177.7dStudy to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderNCT05303064Change from baseline in body mass index (BMI) Zscore at week 12Phase 3RecruitingSep 2026≤ 41 d2026-08-14
APGEApogee Therapeutics, Inc.184.0dA Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With AsthmaNCT06920901Number of Participants with Treatment Emergent Adverse Events (TEAEs)Phase 1Active, not recruitingSep 2026≤ 41 d2026-02-17
ARWRArrowhead Pharmaceuticals163.9dStudy of ARO-DIMERPA in Adult Participants With Mixed HyperlipidemiaNCT07223658Number of Participants with Treatment-Emergent Adverse Events (TEAEs)Phase 1/2Recruiting2026-09-30in 41 d2026-08-18
AVIRAtea Pharmaceuticals, Inc.818.0dC-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCVNCT06868264Proportion of subjects achieving HCV RNA less than the lower limit of quantitation (LLOQ) at study week 24.Phase 3Active, not recruitingSep 2026≤ 41 d2025-12-05
AZNAstraZeneca201.0dA Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerNCT05221840Progression Free Surival (PFS)Phase 3Active, not recruiting2026-09-30in 41 d2026-06-18
AZNAstraZeneca201.0dDurvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCCNCT05557838≥Grade 3 Adverse Events and Adverse Events of Special Interest of Cohort 1Phase 3Active, not recruiting2026-09-30in 41 d2026-06-26
AZNAstraZeneca201.0dA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT06417814Progression free Survival (PFS)Phase 3Recruiting2026-09-30in 41 d2026-05-14
AZNAstraZeneca201.0dClinical& Demographic Profiles of patIents With unControllEd Asthma in Russia: Multi-center oBsErvational ReGistry StudyNCT06521229observationalTo describe the baseline demographic characteristics of outpatients with uncontrolled asthma in the Russian Federation in all patients and in the cohort of patients receiving fixed-dose combination (FDC) budesonide/salbutamol on Visit 2—Recruiting2026-09-30in 41 d2026-04-20
AZNAstraZeneca201.0dReal-world Study Assessing Efficacy of TezepeLumaB in Patients With Severe Asthma Regardless of Phenotype in RussiaNCT06566885observationalChange in ACQ-5 score from baseline—Active, not recruiting2026-09-30in 41 d2026-05-12
AZNAstraZeneca201.0dAn Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma PatientsNCT06605885observationalthe proportion of days covered (PDC) with asthma biologics during 52 weeks—Active, not recruiting2026-09-30in 41 d2026-08-12
AZNAstraZeneca201.0dA Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With DyslipidaemiaNCT07218900Relative change in Low-density lipoprotein cholesterol (LDL-C) from baseline to 12 weeksPhase 2Active, not recruiting2026-09-30in 41 d2026-06-04
AZNAstraZeneca201.0dPrevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)NCT07221331observationalPrevalence of patients with Neurofibromatosis type 1-Plexiform Neurofibromas—Recruiting2026-09-30in 41 d2026-08-12
AZNAstraZeneca201.0dStudy for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology ClinicsNCT07315958observationalPrevalence (number and percentage) of outpatients attending cardiology clinics, with a history of smoking who exhibit concurrent AL consistent with COPD.—Recruiting2026-09-30in 41 d2026-08-14
AZNAstraZeneca201.0dObservational Study on the Prevalence and Risk Factors of Patients With Hyperkalaemia in BrazilNCT07370194observationalPrevalence of Hyperkalemia—Recruiting2026-09-30in 41 d2026-07-24
AZNAstraZeneca201.0dHER2-positive Metastatic Breast Cancer in KazakhstanNCT07593196observational(1) To assess median PFS and PFS rate in patients with HER2-positive mBC receiving anti-HER2 therapy (except for trastuzumab deruxtecan) in routine practice in Kazakhstan—Not yet recruiting2026-09-30in 41 d2026-05-18
BIIBBiogen194.7dA Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErythematosusNCT04895241Percentage of Participants Who Achieved a Systemic Lupus Erythematosus Responder Index of 4 (SRI-4) Response at Week 52Phase 3Active, not recruiting2026-09-30in 41 d2026-02-10
BJDXBluejay Diagnostics, Inc.01.0dMulticenter Symphony IL-6 Monitoring Sepsis ICU Validation StudyNCT06654895observational28-day all-cause mortality [Time Frame: within 28 days after inclusion] participants will be followed up for 28 days—Active, not recruiting2026-09-30in 41 d2026-08-19
BMYBristol-Myers Squibb224.6dA Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid TumorsNCT05888831Number of participants with Dose-Limiting Toxicities (DLTs)Phase 1/2Active, not recruiting2026-09-30in 41 d2025-06-11
BMYBristol-Myers Squibb224.6dDemographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and CanadaNCT07718139observationalNumber of participants with pathological complete response after neoadjuvant immunotherapy and surgical resection.—Active, not recruiting2026-09-30in 41 d2026-07-21
CCCCC4 Therapeutics, Inc.1411.1dStudy to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple MyelomaNCT04756726Phase 1: Safety and tolerability of cemsidomidePhase 1Active, not recruiting2026-09-30in 41 d2026-03-25
CDNACareDx144.3dHeartCare Immuno-optimization in Cardiac Allografts (MOSAIC)NCT05459181Incidence of Allograft loss at 12-months post-transplant (safety)Not applicableNot yet recruitingSep 2026≤ 41 d2024-10-23
CGEMCullinan Therapeutics Inc.1019.2dA Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple MyelomaNCT06381141Proportion of participants reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)Phase 1Active, not recruitingSep 2026≤ 41 d2025-09-18
CHRSCoherus Oncology, Inc.953.6dStudy of CHS-114 in Participants With Advanced Solid TumorsNCT05635643[Arms 1a, 1b, and 2] Rate of Dose Limiting Toxicity (DLT)Phase 1Active, not recruiting2026-09-30in 41 d2026-08-12
CLColgate Palmolive223.8d6-month Clinical Investigation Assessing the Efficacy of an Antimicrobial Mouthrinse in Reducing Established Plaque and Improving Gum HealthNCT07414173Improvement of gum health as measured by the Gingival Index (Löe 1967) between the study groups.Phase 4RecruitingSep 2026≤ 41 d2026-02-17
CLColgate Palmolive223.8dA Study to Investigate Stannous Fluoride Containing Toothpaste on Antibacterial Effects in the Different Regions of the MouthNCT07458464Loe-SilnessPhase 3Not yet recruitingSep 2026≤ 41 d2026-07-28
CLColgate Palmolive223.8dClinical Study to Collect and Analyze Dental Plaque and Oral Health Measures in a Population With High Plaque/Low Gingivitis and High Plaque/High GingivitisNCT07614490Relative abundance of Streptococcus and PorphyromonasPhase 4Recruiting2026-09-30in 41 d2026-05-29
CLColgate Palmolive223.8dComparative Efficacy of Different Dentin Occluding Toothpaste TechnologiesNCT07664592Change from Baseline in Dentin Hypersensitivity (1)Phase 3RecruitingSep 2026≤ 41 d2026-08-07
CORTCorcept Therapeutics136.4dA Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)NCT06108219Percent relative change from Baseline in liver-fat content assessed by MRI-PDFF (Cohort A and Cohort B)Phase 2Active, not recruitingSep 2026≤ 41 d2026-05-08
CORTCorcept Therapeutics136.4dTwo Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid MalignanciesNCT07276373Number of Patients With 1 or More Adverse EventPhase 1/2RecruitingSep 2026≤ 41 d2026-08-19
CYTKCytokinetics209.6dAMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEFNCT06793371Incidence of early drug discontinuationPhase 2RecruitingSep 2026≤ 41 d2026-05-29
DSGNDesign Therapeutics, Inc.1112.0dDT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal DystrophyNCT07024693FECD Biomarkers: Splicing PanelPhase 2RecruitingSep 2026≤ 41 d2025-12-29
EWTXEdgewise Therapeutics, Inc.1312.1dPhase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)NCT05291091Number of adverse events in those treated with sevasemten or placeboPhase 2Active, not recruitingSep 2026≤ 41 d2026-07-31
GILDGilead Sciences233.9dStudy of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus InfectionNCT02932150Incidence of Treatment-Emergent Serious Adverse Events (SAEs) at Week 24Phase 2Active, not recruitingSep 2026≤ 41 d2026-06-18
GILDGilead Sciences233.9dStudy of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)NCT05186974Objective Response Rate as Assessed by Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Phase 2Active, not recruitingSep 2026≤ 41 d2026-02-11
GKOSGlaukos Corporation203.6dEvaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex BlepharitisNCT07400965Percentage of study eyes with elimination of collarettesPhase 2RecruitingSep 2026≤ 41 d2026-02-27
GPCRGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics1011.4dAleniglipron Phase 2 in Type 2 Diabetes MellitusNCT07400588Incidence, severity and relationship of AEs/SAEsPhase 2Active, not recruitingSep 2026≤ 41 d2026-04-27
HLNHALEON191.3dA Study to Evaluate Ibuprofen (IBU) 62.5 mg and Acetaminophen (APAP) 125 mg/5 ml in an Oral Liquid Suspension Fixed-Dose Combination Product in Children Aged 6 to 11 YearsNCT07632274Area Under the Plasma Concentration Versus (Vs.) Time Curve Calculated from Time 0 to the Last Measurable Sampling Time Point (AUC0-t) for Ibuprofen and AcetaminophenPhase 1RecruitingSep 2026≤ 41 d2026-06-30
HLUN-B.COH. Lundbeck A/S0—A Trial of Lu AG13909 in Participants With Congenital Adrenal HyperplasiaNCT05669950Parts A and B: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Phase 1/2Recruiting2026-09-30in 41 d2026-03-09
HTFLHeartFlow, Inc.106.6dThe NAVIGATE-PCI Registry: A New Approach to VIew CT-derived Guidance Ahead of Stenting To Plan Efficient PCINCT07479433observationalPrimary Endpoint—Recruiting2026-09-30in 41 d2026-03-23
IBRXImmunityBio, Inc.1414.5dA Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder CancerNCT02138734Complete Response (CR) RatePhase 1/2Active, not recruiting2026-09-30in 41 d2026-03-31
IRONDisc Medicine, Inc1120.9dStudy of Bitopertin in Participants With EPP or XLP (APOLLO)NCT06910358Average monthly total time in sunlight on days without pain from a phototoxic reaction between 10:00 to 18:00 (10:00 AM to 6:00 PM) after 6 months (24 weeks) of treatmentPhase 3Active, not recruitingSep 2026≤ 41 d2026-08-12
ISRGIntuitive Surgical251.4dCoSMAP Trial: SP-EA vs MP-TA Robot-Assisted Radical ProstatectomyNCT07666217observationalIncidence of postoperative complications and Clavien-Dindo Grade 3a or higher postoperative complications—Active, not recruiting2026-09-30in 41 d2026-06-24
KPTIKaryopharm Therapeutics Inc72.7dA Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated MyelofibrosisNCT04562870Percentage of Participants with Spleen Volume Reduction of Greater Than or Equal to (≥) 35 Percent (%) (SVR35)Phase 2Active, not recruitingSep 2026≤ 41 d2026-07-02
LLYEli Lilly and Company293.9dA Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05536804Percent Change from Baseline in Renal Sinus Fat Content (MRI)Phase 2Active, not recruitingSep 2026≤ 41 d2026-05-08
LLYEli Lilly and Company293.9dA Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)NCT06280703Part A: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration.Phase 1RecruitingSep 2026≤ 41 d2026-01-20
LLYEli Lilly and Company293.9dA Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)NCT06339008Mean Change From Baseline (CFBL) in Total Nasal Symptom Score (TNSS) at Week 16Phase 3Active, not recruitingSep 2026≤ 41 d2026-07-22
LLYEli Lilly and Company293.9dA Study to Compare Two Different Sleep Tests in Participants With No Symptoms or Early Symptoms of Alzheimer's DiseaseNCT07485153observationalPercentage of Agreement between Participants with the Same Results in Sleep Staging Using EEG and Sleep Study—Not yet recruitingSep 2026≤ 41 d2026-03-20
LLYEli Lilly and Company293.9dA Study of Food Effect on Tersolisib (LY4064809) in Healthy ParticipantsNCT07662798Pharmacokinetics (PK): Maximum Concentration (Cmax) of TersolisibPhase 1Active, not recruitingSep 2026≤ 41 d2026-08-19
MAZEMaze Therapeutics1215.9dA Phase 2 Study of MZE829 in Adults With APOL1 Kidney DiseaseNCT06830629Safety and tolerability as assessed by incidence of adverse events (AEs)Phase 2RecruitingSep 2026≤ 41 d2026-07-27
MRNAModernaTX, Inc.1710.2dA Retrospective Study to Characterize Participants With Propionic AcidemiaNCT05769621observationalNumber of Annualized Clinical Event Committee (CEC)-adjudicated Metabolic Decompensation Events (MDEs)—Recruiting2026-09-30in 41 d2026-02-05
NVONovo Nordisk A/S192.9dCharacteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.NCT07154238observationalDescription of characteristics, including clinical, demographic and physical characteristics, among individuals initiated on injectable semaglutide for weight management—Enrolling by invitation2026-09-30in 41 d2025-11-25
NVONovo Nordisk A/S192.9dKorean Real-world Study on MASLD/MASH Outcomes.NCT07739901observationalOccurrence of decompensated cirrhosis—Active, not recruiting2026-09-30in 41 d2026-07-31
NYXH.BRNyxoah S.A.——Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA.NCT05592002Primary Effectiveness EndpointNot applicableActive, not recruitingSep 2026≤ 41 d2025-09-05
ONCBeOne Medicines142.4dA Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy ParticipantsNCT07590102Part A and Part B: Time of the Maximum Observed Concentration (Tmax) of BGB-58067Phase 1Recruiting2026-09-30in 41 d2026-07-22
ORICORIC Pharmaceuticals1113.6dStudy of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 AlterationNCT05315700Recommended Phase 2 Dose (RP2D)Phase 1/2RecruitingSep 2026≤ 41 d2025-08-05
PCSAProcessa Pharmaceuticals21.0dA Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast CancerNCT06568692Evaluation of Objective Response Rate (ORR)Phase 2RecruitingSep 2026≤ 41 d2025-06-19
PFEPfizer194.2dKorea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic ArthritisNCT05754710observationalNumber of patients with treatment emergent treatment-related adverse events—Recruiting2026-09-30in 41 d2026-08-03
RGNXREGENXBIO Inc.133.8dAFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)NCT05693142Part 1 Safety measured by incidence of Adverse Events and Serious Adverse EventsPhase 2/3Active, not recruitingSep 2026≤ 41 d2026-07-21
RXSTRxSight, Inc.134.0dLong-Term Clinical Outcomes Of Subjects Enrolled In The RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment StudyNCT07347379observationalMean absolute manifest refraction spherical equivalent (|MRSE|) at the Long-Term follow up visit—Enrolling by invitationSep 2026≤ 41 d2026-08-12
SGHTSight Sciences, Inc.115.5dA Study of the Helix Surgical System in Primary Open-Angle Glaucoma (POAG) and Cataract (HELIX)NCT06948773≥ 20% change from baseline in mean IOP at the 3-month post-operative endpointNot applicableActive, not recruiting2026-09-30in 41 d2026-07-07
SLNSilence Therapeutics plc113.3dStudy to Assess SLN124 in Patients With Polycythemia VeraNCT05499013Phase 1: Incidence of treatment-emergent adverse events (AEs)Phase 1/2Active, not recruitingSep 2026≤ 41 d2025-12-19
SNDXSyndax Pharmaceuticals1318.6dMAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)NCT06132256Annualized rate of decline in morning pre-dose trough forced vital capacity (FVC) (milliliter [mL])Phase 2Active, not recruitingSep 2026≤ 41 d2026-03-27
SNNSmith & Nephew, Inc.92.6dPost-Market Clinical Study to Evaluate the Safety and Effectiveness of REFLEX ULTRA 45 for Coblation Inferior Turbinate Reduction in ChinaNCT07025304Nasal Obstruction Symptom Evaluation (NOSE) score at 3 MonthsNot applicableRecruiting2026-09-30in 41 d2026-01-07
SNYSanofi172.7dStudy in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in SpainNCT06415175observationalDemographic characteristic of pediatric patients initiating treatment with dupilumab for Severe AD: Age—Active, not recruiting2026-09-30in 41 d2026-02-25
SNYSanofi172.7dPharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy ParticipantsNCT07646548Pharmacokinetic (PK) parameter in serum: Cmax of dupilumabPhase 1Active, not recruiting2026-09-30in 41 d2026-07-21
SUPNSupernus Pharmaceuticals, Inc.139.5dOpen-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)NCT02736656Incidence of adverse eventsPhase 3Active, not recruitingSep 2026≤ 41 d2026-07-15
TNGXTango Therapeutics, Inc.1219.1dStudy of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid TumorsNCT05887492Determine the MTD and RP2D(s) (Phase 1 only)Phase 1/2Active, not recruitingSep 2026≤ 41 d2026-07-06
TRAWTraws Pharma, Inc.15.5dStudy of TRX-100 Evaluating the Safety, Pharmacokinetics, and Food Effect in Healthy VolunteersNCT07526506Incidence, severity, and relationship of treatment-emergent adverse eventsPhase 1RecruitingSep 2026≤ 41 d2026-08-03
TYRATyra Biosciences, Inc917.8dSafety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene AlterationsNCT06160752Phase 1 Part A: To determine the maximum tolerated dose (MTD) of TYRA-200.Phase 1Active, not recruitingSep 2026≤ 41 d2026-08-05
VERAVera Therapeutics, Inc.139.4dMonthly Dosing of Atacicept in IgANNCT07020923Evaluate the effect of atacicept on Gd-IgA1 in patients with IgANPhase 2Active, not recruitingSep 2026≤ 41 d2026-04-13
VNDAVanda Pharmaceuticals129.0dEvaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)NCT04652882Change in Sleep Onset over the treatment period, as measured by sleep diary.Phase 3Active, not recruitingSep 2026≤ 41 d2026-07-27
VNDAVanda Pharmaceuticals129.0dSafety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe OnychomycosisNCT07065773Safety and TolerabilityPhase 2Active, not recruitingSep 2026≤ 41 d2026-02-04
VNDAVanda Pharmaceuticals129.0dAn Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry EyeNCT07179055Corneal StainingPhase 2RecruitingSep 2026≤ 41 d2025-09-17

October 2026 118

TickerNameFamousShortStudyPhaseStatusPrimary completionReadout inUpdated
AMGNAmgen185.2dSingle and Multiple Ascending Dose Study of AMG 513 in Participants With ObesityNCT06585462Number of Participants With Treatment-emergent Adverse Events (TEAE)Phase 1Recruiting2026-10-01in 42 d2026-06-22
AZNAstraZeneca201.0dA Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering DrugsNCT05663515observationalIncidence rate of primary diagnosis of pancreatic cancer among exenatide exposed population—Recruiting2026-10-01in 42 d2026-08-04
BMYBristol-Myers Squibb224.6dA Real-World Study of β-Thalassemia Major Treatment With Luspatercept in TaiwanNCT06596642observationalNumber of Red Blood Cell (RBC) transfusion units received by participants—Active, not recruiting2026-10-01in 42 d2025-06-04
BMYBristol-Myers Squibb224.6dEvaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical PracticeNCT07663786observationalOverall survival (OS) among participants treated with first-line nivolumab—Active, not recruiting2026-10-01in 42 d2026-06-23
COCPCocrystal Pharma, Inc.414.2dA Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain VirusNCT07198139Incidence of norovirus-confirmed diseasePhase 1/2Recruiting2026-10-01in 42 d2026-02-17
NTRANatera, Inc.184.7dThe PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)NCT04091984observationalEfficiency of biopsies—Active, not recruiting2026-10-01in 42 d2024-08-06
NVONovo Nordisk A/S192.9dA Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and InflammationNCT06200207Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score (KCCQ-CSS)Phase 3Active, not recruiting2026-10-01in 42 d2026-07-31
PFEPfizer194.2dImpact and Effectiveness of ABRYSVO® Vaccination During PregnancyNCT06647654observationalRSV-associated LRTD hospitalization among infants—Active, not recruiting2026-10-01in 42 d2026-05-15
AZNAstraZeneca201.0dAZD5305 hADME in Patients With Advanced Solid MalignanciesNCT06713369Absolute bioavailability (F) of SaruparibPhase 1Recruiting2026-10-02in 43 d2026-06-24
PSTVPlus Therapeutics17.8dMultiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal MetastasesNCT07098806Maximum Tolerated DosePhase 1Recruiting2026-10-02in 43 d2025-08-01
MRNAModernaTX, Inc.1710.2dA Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and AdultsNCT05164094Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)Phase 1/2Active, not recruiting2026-10-05in 46 d2026-05-06
SOBI.STSwedish Orphan Biovitrum——A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia MyelofibrosisNCT03165734Spleen volumePhase 3Active, not recruiting2026-10-05in 46 d2026-04-30
BMYBristol-Myers Squibb224.6dA Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary FibrosisNCT06003426Number of participants that experience spontaneous syncopal eventsPhase 3Active, not recruiting2026-10-06in 47 d2026-03-24
REGNRegeneron Pharmaceuticals233.9dStudy to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)NCT02612454Rate of treatment-emergent adverse events (TEAEs) per participant year from baseline through the last study visitPhase 3Active, not recruiting2026-10-07in 48 d2026-05-29
AMGNAmgen185.2dEvaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate CancerNCT06555796Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Phase 1Active, not recruiting2026-10-08in 49 d2026-01-26
AZNAstraZeneca201.0dA Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese PopulationNCT06419413observationalDescriptive summary of demographic and subject characteristic, clinical characteristics and functional deliverables.—Recruiting2026-10-08in 49 d2026-08-18
INCYIncyte Corporation184.8dStudy to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)NCT06958211Proportion of participants who achieve Hidradenitis Suppurativa (HS) Clinical Response 75 (HiSCR75) from baselinePhase 3Active, not recruiting2026-10-09in 50 d2026-07-08
INCYIncyte Corporation184.8dStudy to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)NCT06959225Proportion of participants who achieve Hidradenitis Suppurativa (HS) Clinical Response 75 (HiSCR75) from baselinePhase 3Active, not recruiting2026-10-09in 50 d2026-07-28
PFEPfizer194.2dA Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.NCT06447662Part 1 & 2: Incidence of Adverse Events (AEs)Phase 1Active, not recruiting2026-10-09in 50 d2026-07-22
BMYBristol-Myers Squibb224.6dA Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple MyelomaNCT05372354Number of participants with adverse events (AEs)Phase 1/2Recruiting2026-10-12in 53 d2025-09-05
REGNRegeneron Pharmaceuticals233.9dA Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor TreatmentNCT05133531Percent change in lactate dehydrogenase (LDH)Phase 3Active, not recruiting2026-10-12in 53 d2026-04-30
MRNAModernaTX, Inc.1710.2dA Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy ParticipantsNCT05831111Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)Phase 1Active, not recruiting2026-10-13in 54 d2026-08-11
SNYSanofi172.7dA Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal PolypsNCT06834347Change from baseline in the endoscopic NPSPhase 3Active, not recruiting2026-10-14in 55 d2026-05-20
AZNAstraZeneca201.0dRetention Rate of Acalabrutinib in a Non-interventional SettingNCT05645172observationalRetention rate of CLL—Active, not recruiting2026-10-15in 56 d2025-12-01
AZNAstraZeneca201.0dA Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)NCT07717840Incidence of immediate unsolicited adverse events (AEs)Phase 1/2Recruiting2026-10-15in 56 d2026-07-21
SLDBSolid Biosciences Inc.1116.2dMicrodystrophin Gene Transfer Study in Adolescents and Children With DMDNCT03368742Number of Participants with Treatment Emergent Adverse Events (TEAEs)Phase 1/2Active, not recruiting2026-10-15in 56 d2026-08-10
AZNAstraZeneca201.0dBenralizumab Airway Remodeling Study in Severe Eosinophilic AsthmaticsNCT03953300The change in eosinophil numbers expressed as number/mm2 in submucosa as measured by major basic protein (MBP) staining in endobronchial biopsiesPhase 4Active, not recruiting2026-10-19in 60 d2026-07-28
BMYBristol-Myers Squibb224.6dA Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)NCT05617677Proportion of participants who achieve Systemic Lupus Erythematosus Responder Index-4 [SRI(4)] responsePhase 3Active, not recruiting2026-10-19in 60 d2025-12-03
BMYBristol-Myers Squibb224.6dA Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus ErythematosusNCT05620407Proportion of participants who achieve Systemic Lupus Erythematosus Responder Index-4 [SRI(4)] responsePhase 3Active, not recruiting2026-10-19in 60 d2025-12-02
INCYIncyte Corporation184.8dA Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)NCT06516952Proportion of participants achieving Itch NRS4 and IGA-CPG-S-TS at Week 24Phase 3Active, not recruiting2026-10-19in 60 d2026-05-28
INCYIncyte Corporation184.8dA Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)NCT06516965Proportion of participants achieving Itch NRS4 and IGA-CPG-S-TS at Week 24Phase 3Active, not recruiting2026-10-19in 60 d2026-04-14
INCYIncyte Corporation184.8dA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult ParticipantsNCT07448155Pharmacokinetics Parameter: Cmax of INCA33989 following a single SC administration compared with a single IV infusionPhase 1Recruiting2026-10-19in 60 d2026-07-08
PFEPfizer194.2dA Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisNCT05995964The number of participants achieving ≥75% improvement in EAS175 from baseline at week16.Phase 2Recruiting2026-10-19in 60 d2026-05-04
TEMTempus AI125.9dTempus Priority Study: A Pan-tumor Observational StudyNCT05179824observationalCreate robust data set of health information—Active, not recruiting2026-10-19in 60 d2025-05-06
4568.TDaiichi Sankyo0—First-in-Human Study of DS-3939a in Participants With Advanced Solid TumorsNCT05875168Number of Participants with Dose-limiting Toxicities Following Treatment With DS-3939aPhase 1/2Recruiting2026-10-20in 61 d2026-08-12
BIIBBiogen194.7dA 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusNCT05531565Parts A: Percentage of Participants who Achieve a Cutaneous Lupus Activity of Physician's Global Assessment-Revised (CLA-IGA-R) Erythema Score of 0 or 1Phase 2/3Active, not recruiting2026-10-20in 61 d2026-08-13
AZNAstraZeneca201.0dA Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy ParticipantsNCT07290283Number of participants with adverse events (AEs) and serious adverse events (SAEs)Phase 1Recruiting2026-10-21in 62 d2026-07-31
AMGNAmgen185.2dA Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom StateNCT06245408Change from baseline in ESSPRI scorePhase 3Active, not recruiting2026-10-22in 63 d2026-01-08
AZNAstraZeneca201.0dA Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRASNCT06008093Progression-free survival (PFS) in randomized participantsPhase 2Active, not recruiting2026-10-23in 64 d2026-07-02
NVONovo Nordisk A/S192.9dPatient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in GermanyNCT07653139observationalChoice of treatment alternative in discrete choice tasks—Not yet recruiting2026-10-26in 67 d2026-06-17
AZNAstraZeneca201.0dStudy of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerNCT05775159Objective response rate (ORR)Phase 2Active, not recruiting2026-10-27in 68 d2026-07-02
AZNAstraZeneca201.0dThe Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-managementNCT06909773The number and percentage of COPD in participants with CVD,CHD,AF,CHF.Not applicableRecruiting2026-10-28in 69 d2026-06-26
AZNAstraZeneca201.0dInvestigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy ParticipantsNCT07685600Area under concentration time curve from time 0 to infinity (AUCinf)Phase 1Not yet recruiting2026-10-28in 69 d2026-07-06
SNYSanofi172.7dA Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)NCT04848779observationalProportion of participants alive and free of invasive ventilation at Week 52 of treatment—Active, not recruiting2026-10-28in 69 d2026-06-24
AZNAstraZeneca201.0dPost-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary DiseaseNCT06531798To observe the safety and tolerability of Breztri aerosphereTM as maintenance treatment in Indian patients with moderate to severe COPDPhase 4Recruiting2026-10-30in 71 d2026-07-22
CORTCorcept Therapeutics136.4dEvaluating the Pharmacokinetics and Safety of MiricorilantNCT07553663Assessment of miricorilant PK parametersPhase 1Recruiting2026-10-30in 71 d2026-05-26
MBXMBX Biosciences78.5dA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With ObesityNCT07142707Number of participants with Treatment Emergent Adverse Events (TEAEs)Phase 1Recruiting2026-10-30in 71 d2026-06-09
NVONovo Nordisk A/S192.9dRegulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in KoreaNCT05714683observationalNumber (Incidence) of adverse events (AEs)—Not yet recruiting2026-10-30in 71 d2025-12-05
NYXH.BRNyxoah S.A.——A Post-market Clinical Follow up of the Genio® System for the Treatment of Obstructive Sleep Apnea in AdultsNCT04031040Incidence of device-related Serious Adverse Events (SADEs)Not applicableActive, not recruiting2026-10-30in 71 d2026-03-04
PFEPfizer194.2dA Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and OlderNCT06782282observationalWeighted PCV20 vaccine effectiveness (VE) against Invasive Pneumococcal Disease (IPD)—Active, not recruiting2026-10-30in 71 d2026-04-22
VRTXVertex Pharmaceuticals Incorporated223.0dA Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination TherapyNCT05444257Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Phase 3Active, not recruiting2026-10-30in 71 d2026-07-21
4568.TDaiichi Sankyo0—Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic ImpairmentNCT06740799Pharmacokinetic Parameter: CmaxPhase 1Recruiting2026-10-31in 72 d2026-04-01
ABBVAbbVie224.0dA Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic DermatitisNCT05081557observationalUpadacitinib (UPA) Utilization Patterns—Active, not recruitingOct 2026≤ 72 d2025-08-14
ABBVAbbVie224.0dPivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMDNCT05407636Mean change from baseline in Best Corrected Visual Acuity (BCVA)Phase 3Active, not recruitingOct 2026≤ 72 d2026-08-03
ABBVAbbVie224.0dStudy to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult ParticipantsNCT07680686Number of Participants Experiencing Adverse EventsPhase 1RecruitingOct 2026≤ 72 d2026-08-10
ABOSAcumen Pharmaceuticals109.5dA Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)NCT06335173Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) ScorePhase 2Active, not recruitingOct 2026≤ 72 d2025-10-27
ADAGAdagene Inc511.4dADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid TumorsNCT05405595Maximum tolerated dose (MTD) and RP2D for ADG126 in combination with pembrolizumab.Phase 1/2Recruiting2026-10-31in 72 d2026-01-07
AKBAAkebia Therapeutics108.8dSAD and MAD Study of AKB-9090 in Healthy Adult ParticipantsNCT07429006Number of participants who will report serious Treatment emergent adverse events (TEAEs) and TEAEsPhase 1RecruitingOct 2026≤ 72 d2026-04-13
AMGNAmgen185.2dAnvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).NCT06333951Number of Participants Experiencing Dose Limiting Toxicities (DLT)Phase 1Active, not recruiting2026-10-31in 72 d2026-05-28
AMGNAmgen185.2dA Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)NCT06360354Number of Participants Experiencing Dose Limiting Toxicities (DLT)Phase 1Active, not recruiting2026-10-31in 72 d2026-06-01
AMGNAmgen185.2dA Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)NCT06593522Objective Response (OR) per RECIST 1.1Phase 2Active, not recruiting2026-10-31in 72 d2026-05-28
ANNXAnnexon, Inc.1410.4dA Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)NCT06510816Proportion of Participants Experiencing a Best Corrected Visual Acuity (BCVA) ≥15-letter Loss from Baseline Through Month 15 as Assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Any Two Consecutive VisitsPhase 3Active, not recruiting2026-10-31in 72 d2026-05-04
AZNAstraZeneca201.0dOndexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation)NCT05454787observationalIncidence of adverse drug reactions, Incidence of safety specifications, Incidence of adverse drug reactions by patient background factor—Recruiting2026-10-31in 72 d2026-07-28
AZNAstraZeneca201.0dPhase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian PatientsNCT06429761To assess the safety of trastuzumab deruxtecan in adult Indian patientsPhase 4Recruiting2026-10-31in 72 d2025-11-24
AZNAstraZeneca201.0dCapivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese PatientsNCT06635447Time to first subsequent treatment (TFST) of PIK3CA/AKT1/PTEN-altered population in Cohort 1Phase 3Active, not recruiting2026-10-31in 72 d2026-08-17
BCRXBioCryst Pharmaceuticals1712.4dA Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725NCT06539507Incidence of treatment-emergent adverse events (TEAEs)Phase 1RecruitingOct 2026≤ 72 d2026-06-16
BIIBBiogen194.7dA Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)NCT05925049observationalPercentage of Participants in Natalizumab-Naive and Other MS mAb-Naive Cohort who Start Taking Natalizumab Injections and Develop Anti-Natalizumab Antibodies (ANAs)—Active, not recruiting2026-10-31in 72 d2026-05-13
BMYBristol-Myers Squibb224.6dA Rollover Study of CC-122NCT05688475Number of participants with serious adverse events (SAEs) for participants who received at least 1 dose of CC-122Phase 1Active, not recruiting2026-10-31in 72 d2026-05-11
BMYBristol-Myers Squibb224.6dAsia Myelodysplastic Syndrome (MDS) RegistryNCT07355478observationalParticipant age—Not yet recruiting2026-10-31in 72 d2026-02-13
BNTXBioNTech SE143.3dA Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes LesionsNCT05432583Frequency of solicited local reactions at the injection site (pain, erythema/redness, induration/swelling) recorded up to 7 days after each dosePhase 1Active, not recruitingOct 2026≤ 72 d2025-10-20
BSXBoston Scientific Corporation271.0dA Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBMNCT05303467The number of grade 3-5 non-hematological toxicitiesPhase 1Recruiting2026-10-31in 72 d2026-07-31
BSXBoston Scientific Corporation271.0dcOncomitant Left Atrial aPpendage Closure and Pulsed Field ablaTION-AsiaNCT06686485observationalPeriprocedural or procedure-related Composite Serious Adverse Events will be assessed—Recruiting2026-10-31in 72 d2026-07-23
CBLLCeribell Inc.105.5dCeribell Delirium Monitor Outcomes Pilot StudyNCT07449416Proportion of Participants with Delirium Diagnosed Outside Routine Standard-of-Care AssessmentsNot applicableRecruitingOct 2026≤ 72 d2026-07-22
CLColgate Palmolive223.8dClinical Study to Evaluate Remineralization Using an in Situ Model.NCT07625670Change in integrated mineral loss (Δz)Phase 3Not yet recruitingOct 2026≤ 72 d2026-06-04
CLDXCelldex Therapeutics87.6dA Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaNCT06445023Mean change from baseline to Week 12 of UAS7 (Urticaria Activity Score)Phase 3Active, not recruitingOct 2026≤ 72 d2026-03-25
CLDXCelldex Therapeutics87.6dA Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)NCT06455202Mean change from baseline to Week 12 of UAS7 (Urticaria Activity Score)Phase 3Active, not recruitingOct 2026≤ 72 d2026-03-25
CORTCorcept Therapeutics136.4dDazucorilant in Patients With Amyotrophic Lateral SclerosisNCT05407324Change from Baseline to Week 24 in the ALS Functional Rating Scale-Revised (ALSFRS-R) total score.Phase 2RecruitingOct 2026≤ 72 d2026-06-16
CRNXCrinetics Pharmaceuticals Inc.71.8dA Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's SyndromeNCT05804669Proportion of participants with treatment emergent adverse events (TEAEs)Phase 1/2Active, not recruitingOct 2026≤ 72 d2026-08-19
GEHCGE Healthcare212.9dPortrait Mobile Monitoring Solution V2.0 External EvaluationNCT07309809Collection of user feedback surveys from CliniciansNot applicableNot yet recruitingOct 2026≤ 72 d2026-06-10
GEHCGE Healthcare212.9dNMT EasyFit Sensor and CableNCT07394140Collection of End User Feedback SurveysNot applicableRecruiting2026-10-31in 72 d2026-07-08
GILDGilead Sciences233.9dStudy of Sacituzumab Govitecan in Patients With Solid TumorNCT05119907Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1) By Investigator AssessmentPhase 2Active, not recruitingOct 2026≤ 72 d2025-11-17
GILDGilead Sciences233.9dStudy of GS-4528 in Adults With Solid TumorsNCT05840224Percentage of Participants Experiencing Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Phase 1Active, not recruitingOct 2026≤ 72 d2026-07-27
HLNHALEON191.3dA Study to Investigate the Efficacy of an Experimental Dentifrice Containing Stannous Fluoride in Improving Gingival HealthNCT07704905Change from Baseline in Overall Modified Gingival Index (MGI) at Week 8Not applicableRecruitingOct 2026≤ 72 d2026-08-12
HNGEHinge Health, Inc154.0dA Comprehensive Digital Care Program for Migraine ManagementNCT07642414Mean Change in Monthly Migraine Days (MMDs)Not applicableRecruitingOct 2026≤ 72 d2026-06-16
IBAB.BRIon Beam Applications——Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Sichuan)NCT07152353Short term efficacy evaluationNot applicableActive, not recruitingOct 2026≤ 72 d2026-01-07
IBAB.BRIon Beam Applications——Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Shenzhen)NCT07153094Short term efficacy evaluationNot applicableActive, not recruitingOct 2026≤ 72 d2026-01-16
IBRXImmunityBio, Inc.1414.5dA Study to Assess Anktiva in Patients With Long Covid-19.NCT07108036Incidence of treatment emergent adverse events (TEAEs) through 30 days post final study drug administration.Phase 2RecruitingOct 2026≤ 72 d2026-05-11
IDYAIDEAYA Biosciences1113.2dA Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsNCT05787587Part 1 (Dose Escalation): To characterize the safety and tolerability of IDE161 monotherapy or in combination with pembrolizumab to determine the MTD and/or RDEPhase 1Active, not recruitingOct 2026≤ 72 d2026-07-13
IMCRImmunocore Ltd1417.4dSafety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint InhibitorsNCT04262466Phase 1: Incidence of dose-limiting toxicity (DLT)sPhase 1/2Active, not recruitingOct 2026≤ 72 d2026-03-06
IRONDisc Medicine, Inc1120.9dStudy of DISC-0974-201 in Participants With IBD and AnemiaNCT07368972Maximal change from baseline in Hgb through Day 85Phase 2RecruitingOct 2026≤ 72 d2026-08-03
JANXJanux Therapeutics157.7dStudy of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.NCT07291323Incidence, severity, and relatedness of TEAEs, treatment-emergent SAEs, and treatment-emergent AESIs.Early Phase 1RecruitingOct 2026≤ 72 d2026-04-23
JBIOJade Biosciences, Inc.1211.5dA Phase 1 Study of JADE101 in Healthy ParticipantsNCT07059312Safety and Tolerability of Single Ascending Doses of JADE101 in Healthy ParticipantsPhase 1Active, not recruitingOct 2026≤ 72 d2025-12-18
LLYEli Lilly and Company293.9dA Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)NCT04088396Percentage of Participants Achieving Adapted Pediatric American College of Rheumatology 30 Responder Index (PediACR30) Response Criteria at Week 12Phase 3Active, not recruitingOct 2026≤ 72 d2026-08-11
LLYEli Lilly and Company293.9dEffect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)NCT06297603Change from Baseline in Hemoglobin A1c (HbA1c) (%)Phase 3Active, not recruitingOct 2026≤ 72 d2026-07-20
LLYEli Lilly and Company293.9dA Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal FunctionNCT07426380Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity AUC(0-∞) of LY3841136Phase 1Active, not recruitingOct 2026≤ 72 d2026-08-19
LLYEli Lilly and Company293.9dA Study of Eloralintide (LY3841136) in Healthy ParticipantsNCT07701083Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of EloralintidePhase 1Not yet recruitingOct 2026≤ 72 d2026-07-14
LLYEli Lilly and Company293.9dA Study of LY4268989 (MORF 057) in Healthy ParticipantsNCT07707375Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4268989Phase 1Not yet recruitingOct 2026≤ 72 d2026-07-16
MIRMMirum Pharmaceuticals, Inc.1012.1dEvaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)NCT06553768Mean change in the ItchRO(Obs) severity scorePhase 3Active, not recruitingOct 2026≤ 72 d2026-08-11
NTHINeonc Technologies, Inc.211.9dA Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain TumorsNCT06357377Nature and severity of adverse eventsPhase 1Not yet recruitingOct 2026≤ 72 d2026-01-14
NTRANatera, Inc.184.7dProspera Test Evaluation in Cardiac Transplant (ProTECT)NCT05205551observationalPrimary Endpoints:—Active, not recruiting2026-10-31in 72 d2025-05-22
OGNOrganon and Co146.2dTapinarof for the Treatment of Plaque Psoriasis in Pediatric SubjectsNCT05172726Adverse Events (AEs) and Serious Adverse Events (SAEs)Phase 3Active, not recruitingOct 2026≤ 72 d2026-04-17
OLMAOlema Pharmaceuticals, Inc.1018.2dOP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT06016738Dose-Selection Part: Incidence of adverse eventsPhase 3Active, not recruiting2026-10-31in 72 d2026-08-13
PHATPhathom Pharmaceuticals, Inc.128.7dA Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 WeeksNCT06851559Number of Participants at Week 12 Achieving Peak Esophageal Intraepithelial Eosinophil Count <15 eos/hpf.Phase 2Active, not recruitingOct 2026≤ 72 d2026-06-29
PHIL.MIPhilogen S.p.A.——Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed GlioblastomaNCT04443010For Phase 1: DLTPhase 1/2RecruitingOct 2026≤ 72 d2023-10-10
PLSEPulse Biosciences, Inc.67.0dNS-PFA Catheter Ablation of Paroxysmal Atrial Fibrillation With the Pulse Biosciences CellFX SystemNCT07018596Proportion of participants with freedom from primary safety endpointNot applicableRecruitingOct 2026≤ 72 d2026-05-06
REPLReplimune, Inc.143.3dStudy of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid TumorsNCT04336241Percentage of adverse events (AEs)Phase 1Active, not recruiting2026-10-31in 72 d2026-02-27
RMDResMed1514.2dRegistry Study on Prescription, Patient Pathways, Therapy Efficacy and Usage of Mandibular Advancement Devices in Obstructive Sleep Apnea - PATT-OSA RegistryNCT03924817observationalChanges of the Apnoea-Hypopnea-Index (AHI) at baseline compared to a follow-up after 3 months—Active, not recruiting2026-10-31in 72 d2026-08-13
RMDResMed1514.2dCircadian Rhythm Monitoring StudyNCT07336654Feasibility of estimating circadian phase with the myCircadian wearable device. CorrelationNot applicableNot yet recruitingOct 2026≤ 72 d2026-05-19
RMDResMed1514.2dExploration of Current and New Technologies for Accuracy of Diagnosing OSANCT07485582observationalSensitivity—Not yet recruitingOct 2026≤ 72 d2026-08-19
RYTMRhythm Pharmaceuticals, Inc.1716.2dA Study of Setmelanotide in Patients With Prader-Willi SyndromeNCT06772597Frequency and severity of adverse events (AEs)Phase 2Active, not recruiting2026-10-31in 72 d2026-02-12
SRPTSarepta Therapeutics, Inc.158.8dA Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)NCT03992430Part 1: Incidence of Adverse Events (AEs)Phase 3Active, not recruiting2026-10-31in 72 d2026-02-27
SYRESpyre Therapeutics, Inc.1413.5dA Study of SPY072 in Rheumatic DiseaseNCT07148414Rheumatoid Arthritis: Change from baseline in Disease Activity Score in 28 joints (c-reactive protein) (DAS-CRP)Phase 2Active, not recruiting2026-10-31in 72 d2026-06-05
TGTXTG Therapeutics, Inc.1713.6dA Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast MilkNCT06143514observationalArea Under the Milk Concentration-time Curve from Time 0 to Infinity (AUC0-inf) of BRIUMVI™—Recruiting2026-10-31in 72 d2026-07-20
TGTXTG Therapeutics, Inc.1713.6dA Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)NCT07211633Area Under the Curve From Week 0 to Week 24 (AUC0-W24) of UblituximabPhase 3Active, not recruiting2026-10-31in 72 d2026-07-17
TMDXTransMedics129.5dOCS DCD Heart + CAP Continued Follow-UpNCT05741723observationalPatient survival—Active, not recruitingOct 2026≤ 72 d2025-09-09
VNDAVanda Pharmaceuticals129.0dEvaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled HypertensionNCT07090161Change from baseline to treatment week 4 in SiSBPPhase 2RecruitingOct 2026≤ 72 d2026-02-27
XENEXenon Pharmaceuticals Inc.167.3dA Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)NCT05716100Median percent change (MPC) in focal seizure frequency from baseline to DBP for XEN1101 versus placebo.Phase 3RecruitingOct 2026≤ 72 d2026-05-14
ZBHZimmer Biomet194.9dHi-Fatigue G Bone Cement Retrospective StudyNCT06699134observationalRadiographic evaluation—RecruitingOct 2026≤ 72 d2025-12-02

November 2026 33

TickerNameFamousShortStudyPhaseStatusPrimary completionReadout inUpdated
BMYBristol-Myers Squibb224.6dA Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I DisorderNCT06951698Change from baseline in Young Mania Rating Scale (YMRS) scorePhase 3Recruiting2026-11-01in 73 d2026-07-27
CRBPCorbus Pharmaceuticals Inc.79.4dFirst-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.NCT06603844Occurance of Dose-limiting toxicitiesPhase 1/2Recruiting2026-11-01in 73 d2025-06-03
ERASErasca, Inc.177.3dA Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid TumorsNCT04866134Evaluate safety and tolerability of escalating doses of ERAS-007 BID-QWPhase 1/2Active, not recruiting2026-11-01in 73 d2026-06-22
EWEdwards Lifesciences231.8dALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt SystemNCT05686317Device + Medical Therapy: Subjects with Early Major Adverse EventsNot applicableActive, not recruiting2026-11-01in 73 d2026-06-04
SRRKScholar Rock, Inc.1516.2dLong-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of ApitegromabNCT05626855Evaluate the long-term safety and tolerability of apitegromab in patients with Type 2 and Type 3 SMAPhase 3Active, not recruiting2026-11-01in 73 d2025-05-25
AZNAstraZeneca201.0dA Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus ErythematosusNCT06015737Number of participants with a 70% reduction relative to baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) scorePhase 3Active, not recruiting2026-11-02in 74 d2026-07-29
AZNAstraZeneca201.0dOverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR AmyloidosisNCT06355934observationalHealth Care Resource Utilization (HCRU) - Outpatient visits—Recruiting2026-11-02in 74 d2026-08-11
BMYBristol-Myers Squibb224.6dA Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)NCT06951711Change from baseline in Young Mania Rating Scale (YMRS) scorePhase 3Recruiting2026-11-02in 74 d2026-08-18
DXCMDexCom, Inc.203.5dContinuous Glucose Monitoring By DExcom iN PEople Followed for Type 2 DIabeTes on Insulin Therapy in the Kingdom of Saudi ArabiaNCT07603284Change in HbA1cPhase 4Active, not recruiting2026-11-02in 74 d2026-05-22
REGNRegeneron Pharmaceuticals233.9dA Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 MelanomaNCT06190951Pathological complete response (pCR) rate as assessed by Blinded Independent Pathological Review (BIPR)Phase 2Active, not recruiting2026-11-02in 74 d2026-02-10
INCYIncyte Corporation184.8dRollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)NCT04509700Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Phase 2Active, not recruiting2026-11-05in 77 d2026-06-25
REGNRegeneron Pharmaceuticals233.9dExtension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)NCT04515524observationalBinocular best-corrected visual acuity (BCVA)—Active, not recruiting2026-11-05in 77 d2026-03-27
PFEPfizer194.2dSafety and Efficacy of Xalkori ROS1NCT03375242observationalThe incidence of adverse drug reactions in this surveillance.—Active, not recruiting2026-11-06in 78 d2026-03-30
SNYSanofi172.7dA Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal PolypsNCT06834360Change from baseline in the endoscopic NPSPhase 3Active, not recruiting2026-11-06in 78 d2026-06-02
AZNAstraZeneca201.0dTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)NCT04784715Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessmentPhase 3Active, not recruiting2026-11-11in 83 d2026-07-30
AZNAstraZeneca201.0dGYNGHER - HER2 Expression in Gynecological Malignancies: a Brazilian CohortNCT07101081observationalHER2 IHC status as per Dako HercepTest and gastric cancer scoring criteria.—Recruiting2026-11-11in 83 d2026-07-22
AZNAstraZeneca201.0dA Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic ImpairmentNCT07343960Area under concentration time curve from zero to infinity (AUCinf)Phase 1Recruiting2026-11-11in 83 d2026-07-02
PGENPrecigen, Inc1011.1dPRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical CancerNCT06157151Determine the Objective Response Rate (ORR) following treatment with PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.Phase 2Recruiting2026-11-11in 83 d2026-04-23
4523.TEisai Inc.0—A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy ParticipantsNCT07766369Part A, area under concentration versus time curve from zero time (predose) to time of last quantifiable concentration AUC(0-t) of E2086 and its Metabolite M1Phase 1Not yet recruiting2026-11-12in 84 d2026-08-14
PFEPfizer194.2dEvaluating the Benefits of RSV Maternal Vaccination Using a Scottish National DatasetNCT07235397observationalPCR-confirmed RSV-associated LRTD hospitalization occurring ≤180 days after birth (first episode)—Not yet recruiting2026-11-13in 85 d2026-07-01
REGNRegeneron Pharmaceuticals233.9dA Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced CancersNCT04626635The incidence of Dose-Limiting Toxicities (DLTs) during the DLT periodPhase 1/2Active, not recruiting2026-11-13in 85 d2026-07-02
REGNRegeneron Pharmaceuticals233.9dStudy of Olatorepatide in Adult Participants Living With Overweight or Obesity in the USNCT07431086Occurrence of Treatment-Emergent Adverse Events (TEAEs)Phase 2Active, not recruiting2026-11-13in 85 d2026-06-17
ACHVAchieve Life Sciences715.0dPhase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E CigarettesNCT07392125Primary Efficacy ObjectivePhase 3Not yet recruiting2026-11-15in 87 d2026-02-06
AMGNAmgen185.2dA Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes MellitusNCT07160257Change from Baseline in M-value from Hyperinsulinemic-euglycemic Clamp at Week 25Phase 1Active, not recruiting2026-11-15in 87 d2026-06-12
AZNAstraZeneca201.0dNational Acalabrutinib Observational StudyNCT05437250observationalTime to Discontinuation—Active, not recruiting2026-11-15in 87 d2026-05-28
AZNAstraZeneca201.0dAZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2NCT06219941Incidence of adverse events (AEs), serious AEs (SAEs). Changes from baseline in clinical laboratory parameters, vital signs, ECGs and physical examination. Rate of AEs leading to discontinuation of AZD0901, Occurrence of DLTs.Phase 2Recruiting2026-11-17in 89 d2026-07-29
BMYBristol-Myers Squibb224.6dA Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.NCT07283263Number of participants with treatment-emergent adverse events (AEs)Phase 1Recruiting2026-11-17in 89 d2026-01-07
SOBI.STSwedish Orphan Biovitrum——A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa ProphylaxisNCT06752850Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) synovial hypertrophy domain score decrease.Phase 4Active, not recruiting2026-11-17in 89 d2026-04-30
AMGNAmgen185.2dEffect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or ObesityNCT07523711Maximum Observed Concentration (Cmax) of COCPhase 1Active, not recruiting2026-11-18in 90 d2026-07-20
AZNAstraZeneca201.0dA Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy ParticipantsNCT07723833Maximum observed drug concentration (Cmax)Phase 1Recruiting2026-11-18in 90 d2026-08-03
BMYBristol-Myers Squibb224.6dA Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's SyndromeNCT05946941Change from baseline in European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 52Phase 3Active, not recruiting2026-11-18in 90 d2026-04-01
NVAXNovavax1416.6dEfficacy and Safety of NVX-CoV2705NCT07086222First episode of PCR-positive symptomatic COVID 19Phase 4Active, not recruiting2026-11-18in 90 d2026-05-08
SYRESpyre Therapeutics, Inc.1413.5dA Study of SPY003-207 in Healthy VolunteersNCT06873724Treatment emergent adverse eventsPhase 1Active, not recruiting2026-11-18in 90 d2026-03-20

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Related →Calendar (CAL)Screener (SCR)Watchlist (WL)